Patients in the high-intensity statin group had higher prevalence of ST-elevation myocardial infarction (27.7% vs. 22.7%), non-ST-elevation myocardial infarction (36.7% vs. 23.4%), and potent P2Y12 inhibitor use (17.2% vs. 9.2%) than the moderate-intensity statin with ezetimibe group. The gene discussed is P2RY12; the disease is ST Elevation Myocardial Infarction.